



# Optimise-FLT3: trial schema




Allogeneic HSCT in 1<sup>st</sup> CR recommended for:

- *FLT3*+/*NPM1*+ with PB *NPM1* qPCR+ post cycle 2
- *FLT3*+/*NPM1*- patients with baseline *FLT3m*≥5%



24 months follow-up, including 3-monthly bone marrow qPCR MRD assessment for patients with *FLT3*+/*NPM1*+



24 months follow-up, including 3-monthly bone marrow qPCR MRD assessment for patients with *FLT3+*/*NPM1+*

**\*Allogeneic haematopoietic stem cell transplant in 1<sup>st</sup> complete remission**

Recommended for:

- *FLT3+*/*NPM1+* patients with PB NPM1 qPCR+ post cycle 2
- *FLT3+*/*NPM1-* patients with baseline *FLT3* mutation level of  $\geq 5\%$
- *NPM1-* patients allocated to flow MRD monitoring who are flow MRD positive ( $>0.1\%$ ) by central testing
- Patients with ELN 2022 adverse risk disease or NUP98 rearrangement.

Generally:

- Myeloablative conditioning following cycle 2 where practical for patients  $\leq 40$ -45yrs
- Reduced intensity conditioning (RIC) following cycle 3 for patients aged  $\geq 40$ -45yrs